Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Immunoregulatory protein B7-H3 promotes growth and decreases sensitivity to therapy in metastatic melanoma cells.

Pigment cell & melanoma research - 1 Sept 2017

Flem-Karlsen Karine, Tekle Christina, Andersson Yvonne, Flatmark Kjersti, Fodstad Øystein, Nunes-Xavier Caroline E

Abstract excerpt

B7-H3 (CD276) belongs to the B7 family of immunoregulatory proteins and has been implicated in cancer progression and metastasis. In this study, we found that metastatic melanoma cells with knockdown expression of B7-H3 showed modest decrease in proliferation and glycolytic capacity and were more sensitive to dacarbazine (DTIC) chemotherapy and small-molecule inhibitors targeting MAP kinase (MAPK) and AKT/mTOR...

Topics

Join the communities discussing this publication.

Benzimidazoles
Dacarbazine
Everolimus
Gene Knockdown Techniques
Glycolysis

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 28513992
DOI: 10.1111/pcmr.12599

Genes

BRAF

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 1 Sept 2026.

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

0

discussions

0

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Immunoregulatory protein B7-H3 promotes growth and decreases sensitivity to therapy in metastatic melanoma cells.PMID 28513992Read ↗

B7-H3 is associated with the armored-cold phenotype and predicts poor immune checkpoint blockade response in melanoma.Semantic proximity Read ↗

To kill a cancer: Targeting the immune inhibitory checkpoint molecule, B7-H3Semantic proximity Read ↗

Decreased expression of B7-H3 reduces the glycolytic capacity and sensitizes breast cancer cells to AKT/mTOR inhibitorsSemantic proximity Read ↗

B7-H3 and its relevance in cancer immunological and non-immunological perspectivesSemantic proximity Read ↗

The novel non‐immunological role and underlying mechanisms of B7‐H3 in tumorigenesisSemantic proximity Read ↗

B7H3 regulates differentiation and serves as a potential biomarker and theranostic target for human glioblastomaSemantic proximity Read ↗

ITC-6102RO, A Novel B7-H3 Antibody-Drug Conjugate, Exhibits Potent Therapeutic Effects against B7-H3 Expressing Solid TumorsSemantic proximity Read ↗

High B7-H3 protein expression in Medulloblastoma is associated with metastasis and unfavorable patient outcomesSemantic proximity Read ↗

Large-scale analysis reveals the specific clinical and immune features of B7-H3 in gliomaSemantic proximity Read ↗

Integrative molecular analyses define correlates of high B7-H3 expression in metastatic castrate-resistant prostate cancerSemantic proximity Read ↗

Overexpression of B7-H3 Is Associated With Poor Prognosis in Laryngeal CancerSemantic proximity Read ↗

Role of MYC-miR-29-B7-H3 in Medulloblastoma Growth and AngiogenesisSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.